Inhibiting matrix metalloproteinases with prinomastat produces abnormalities in fetal growth and development in rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 77, Issue 2, 2006, Pages 95-103

  Younis, Husam S ^a   Jessen, Bart A ^a   Wu, Ellen Y ^a   Stevens, Gregory J ^a  

^a PFIZER INC   (United States)

Author keywords

Embryo fetal toxicity; Matrix metalloproteinase inhibitors; Matrix metalloproteinases; Prinomastat; Rat embryo cultures; Rats

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CESAREAN SECTION; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; EMBRYO CULTURE; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; FEMALE; FETUS DEVELOPMENT; FETUS GROWTH; FOOD INTAKE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RAT; SOFT TISSUE DEFECT;

ANIMALS; BODY WEIGHT; BONE AND BONES; EATING; EMBRYO; EMBRYO CULTURE TECHNIQUES; EMBRYO LOSS; ENZYME INHIBITORS; FEMALE; FETUS; MATRIX METALLOPROTEINASES; ORGAN SIZE; ORGANIC CHEMICALS; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; UTERUS;

ANIMALIA;

EID: 33646427750     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20073     Document Type: Article

References (41)

1. Alexander CM, Hansell RJ, Behrendtsen O, Flannery ML, Kishnani NS, Hawkes SP, Werb Z. 1996. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 122:1723-1736.
2. Behrendt C. 2004. Visual acuity and its decrease in classic neovascular age-related macular degeneration. Ophthalmic Epidemiol 11:359-367.
3. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA. 2005. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23:842-849.
4. Brown NA, Fabro S. 1981. Quantitation of rat embryonic development in vitro: a morphological scoring system. Teratology 24:65-78.
5. Brown PD. 1997. Matrix metalloproteinase inhibitors. Angiogenesis 1:142-154.
6. Butler TA, Zhu C, Mueller RA, Fuller GC, Lemaire WJ, Woessner JF. 1991. Inhibition of ovulation in the perfused rat ovary by a synthetic collagenase inhibitor SC44463. Biol Reprod 44:1183-1188.
7. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. 2003. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285.
8. Cockroft DL. 1990. Dissection and culture of postimplantation embryos. In: Copp AJ, Cockroft DL, editors. Postimplantation mammalian embryos: a practical approach. New York: Oxford University Press, p 15-39.
9. Curry TE, Osteen KG. 2001. Cyclic changes in the matrix metalloproteinase system in the ovary and uterus. Biol Reprod 64:1285-1296.
10. Curry TE, Osteen KG. 2003. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 24:428-465.
11. Del Bigio MR, Seyoum G. 1999. Effect of matrix metalloproteinase inhibitors on rat embryo development in vitro. Cells Tissues Organs 165:67-73.
12. Dubois B, Arnold B, Opdenakker G. 2000. Gelatinase B deficiency impairs reproduction. J Clin Invest 106:627-628.
13. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, Shimada H, DeClerck YA, Gomer CJ. 2004. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 64:2328-2332.
14. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. 2004. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48:411-424.
15. Goldman S, Shalev E. 2003. The role of the matrix metalloproteinases in human endometrial and ovarian cycles. Eur J Obstet Gynecol Reprod Biol 111:109-121.
16. Hirvonen, R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. 2003. Matrix metalloproteinase- (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 77:85-91.
17. Holmbeck K, Bianco P, Caterina J, Yamado S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H. 1999. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connective tissue disease due to inadequate collagen turnover. Cell 99:81-92.
18. Holmbeck K, Bianco P, Chrysovergis K, Yamado S, Birkedal-Hansen H. 2003. MT1-MMP-dependent, apoptotic remodeling of unmineralized cartilage: a critical process in skeletal growth. J Cell Biol 163:661-671.
19. Hurst PR, Palmay RD. 1999. Matrix metalloproteinases and their endogenous inhibitors during the implantation period in the rat uterus. Reprod Fertil Dev 11:395-402.
20. Jeziorska M, Nagase H, Salamonsen LA, Woolley DE. 1996. Immunolocalization of the matrix metalloproteinases gelatinase B and stromelysin 1 in human endometrium throughout the menstrual cycle. J Reprod Fertil 107:43-51.
21. Kavlock RJ, Chernoff N, Rogers EH. 1985. The effect of acute maternal toxicity on fetal development in the mouse. Teratog Carcinog Mutagen 5:3-13.
22. MO). J Clin Invest 115:2832-2842.
23. Kher KS. 1985. Maternal toxicity: A possible etiology factor in embryo-fetal deaths and fetal malformations of rodent-rabbit species. Teratology 31:129-153.
24. Kimura A, Kihara T, Ohkura R. 2001. Localization of bradykinin B2 receptor in the follicles of porcine ovary and increased expression of matrix metalloproteinase-3 and 20 in cultured granulose cells by bradykinin treatment. Biol Reprod 65:1462-1470.
25. Liu J, Tsao MS, Pagura M, Shalinsky DR, Khoka R, Fata J, Johnston MR. 2003. Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Lung Cancer 42:335-344.
26. Liu K, Wahlberg P, Ny T. 1998. Coordinated and cell-specific regulation of membrane type matrix metalloproteinase 1 (MT1-MMP) and its substrate matrix metalloproteinase 2 (MMP-2) by physiological signals during follicular development and ovulation. Endocrinology 139:4735-4738.
27. Page-McCaw A, Serano J, Sante JM, Rubin GM. 2003. Drosophila matrix metalloproteinases are required for tissue remodeling, but not embryonic development. Dev Cell 4:95-100.
28. Rechtman MP, Zhang J, Salamonsen LA. 1999. Effect of inhibition of matrix metalloproteinases on endometrial decidualization an implantation in mated rats. J Reprod Fertil 117:169-177.
29. Rudolph-Owens L, Hulboy DL, Wilson CL, Mudgett J, Matrisian LM. 1997. Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology 138:4902-4911.
30. Salamonsen LA, Woolley DE. 1999. Menstruation: induction by matrix metalloproteinases and inflammatory cells. J Reprod Immunol 44:1-27.
31. Santos O, McDermott CD, Daniels RG, Appelt K. 1997. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 15:499-508.
32. Scatena R. 2000. Prinomastat, a hydroxamate-basecl matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodeling-related diseases. Expert Opin Investig Drugs 9:2159-2165.
33. Schardein JL. 1987. Approaches to defining the relationship of maternal and developmental toxicity. Teratogen Carcinogen Mutagen 7:255-271.
34. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Trultt G, Wood A, Varki NM, Appelt K. 1999a. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 878:236-270.
35. Shalinsky DR, Brekken J, Zou H, Kolis S, Wood A, Webber S, Appelt K. 1999b. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Investig New Drugs 16:303-313.
36. Sottile J. 2004. Regulation of angiogenesis by extracellular matrix. Biochim Biophys Acta 1654:13-22.
37. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A. 2002, MT1-MMP expression promotes tumor growth and angiogenesis through upregulation of vascular endothelial growth factor expression. FASEB J 16:555-564.
38. Vihinen P, Ala-aho R, Kahari VM. 2005. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5:203-220.
39. Werb Z, Chin JR. 1998. Extracellular matrix remodeling during morphogenesis. Ann NY Acad Sci 857:110-118.
40. Wilson CL, Heppner KJ, Rudolph LA, Matrisian LM. 1995. The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol Biol Cell 6:1402-1407.
41. Zucker S, Vacirca J. 2004. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101-117.